Zacks Investment Research
10 Sept 2026, 16:55 UTC · 15h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
AbbVie expects combined sales for Skyrizi and Rinvoq to exceed $31 billion in 2026. — This provides a concrete, high-value revenue target that confirms the successful replacement of Humira's lost exclusivity.
+0.60The immunology segment generated $16.1 billion in H1 2026, growing nearly 16% year-over-year. — Strong realized growth in the company's primary revenue driver validates the current bullish trajectory.
+0.50FDA review is underway for Rinvoq's vitiligo and alopecia areata indications, which could add up to $2 billion in peak sales. — Upcoming regulatory approvals represent incremental upside and potential catalysts for the stock price.
+0.40Continue reading
5 related stories
Search tags
Phase III data for Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected later in 2026. — Clinical trial results are binary events that could further extend the growth runway for the immunology franchise.
Which stocks this story touches
The company is experiencing strong top-line growth driven by the success of Skyrizi and Rinvoq, successfully offsetting Humira's erosion.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
11h ago
